The hope of curing cancer has a name:
Gustave Roussy
As France’s and Europe’s leading cancer centre, and ranked the world’s sixth best oncology hospital by Newsweek, Gustave Roussy is an institute of care, research, and education that treats patients with all types of cancer, at every age and every stage of life. Its expertise in rare cancers and complex tumours is internationally recognised.
Gustave Roussy brings together medical, scientific, and technological excellence and carries the bold ambition of curing 80% of patients with cancer by 2040.
Gustave Roussy — Europe’s leading cancer centre
- Number one by patient volume: more than 52,000* patients cared for, including nearly 2,700 in paediatrics
- Number one for its unique model of integrated research: over 6,100* patients enrolled in clinical studies, giving them access to innovative treatments
- Number one for research activity and scientific output: 1,200* scientific publications, including 223* international papers in journals with an Impact Factor between 10 and 30 (excluding conferences)
*2024 data
► See our 
2024 Annual Report
Global research with a societal impact
The Institute integrates fundamental, translational, and clinical research, all sources of therapeutic innovation.
Gustave Roussy’s research is focused primarily on personalised medicine, immunotherapy, and DNA repair, making it today Europe’s leading centre for personalised medicine and immunotherapy.
Cutting-edge medicine serving humanity
Gustave Roussy’s teams are constantly innovating to deliver the highest-quality care — ever more personalised and less invasive — with one objective: to optimise every patient’s care pathway.
The Institute combines innovation and humanity, addressing not only medical treatment but also patients’ physical, psychological, and social quality of life.
Its state-of-the-art facilities include:
- robotic surgery,
- outpatient surgery and interventional radiology suites,
- a fully renovated radiotherapy unit,
- two robotic chemotherapy preparation systems,
- and a next-generation genomics platform.
Gustave Roussy currently ranks first in Europe for early-phase clinical trials, thanks to its dedicated department, DITEP, which enables patients to access innovative medicines in record time.
Education
Through its education division, Gustave Roussy supports all those involved in the fight against cancer and anticipates future transformations in oncology.
The Institute trains tomorrow’s oncology professionals through Gustave Roussy Education, affiliated with Université Paris-Saclay.
It is also home to the Doctoral School of Oncology, the only single-theme doctoral school entirely dedicated to cancer research.
Discover Gustave Roussy by video
